This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.

bioRxiv · Feb 9, 2022Microbiology

In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.

L. Checkmahomed, V. Du Pont, N. C. Riola, J. Perry, J. Li, D. P. Porter, G. Boivin

This study shows that remdesivir resistance in SARS-CoV-2 develops slowly, with a single mutation conferring limited resistance.

bioRxiv · Feb 7, 2022Microbiology

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

A. Schafer, D. R. Martinez, J. J. Won, F. R. Moreira, A. J. Brown, K. L. Gully, R. Kalla, K. Chun, V. Du Pont, D. Babusis, J. Tang, E. Murakami, R. Subramanian, K. T. Barrett, B. J. Bleier, , T. P. Sheahan

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

bioRxiv · Sep 13, 2021 · PreprintMicrobiology

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology